查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1594668

阿片类药物引起的便秘市场：按活性成分、药物类别、给药方式、分销管道划分 - 2025-2030 年全球预测

Opioid Induced Constipation Market by Active Ingredients, Drug Class, Mode of Administration, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年阿片类药物引起的便秘市场价值为6595万美元，预计到2024年将达到7010万美元，复合年增长率为6.69%，预计到2030年将达到1.0378亿美元。

阿片类药物引起的便秘（OIC）是使用阿片类镇痛药进行疼痛管理的患者常见的副作用，已成为製药公司和医疗保健提供者关注的重要领域。慢性疼痛的增加和阿片类药物消费量的增加增加了对有效的 OIC 管理解决方案的需求。主要用途包括处方药、非处方药和旨在缓解便秘症状的非药物干预措施。最终用户范围从医院到居家照护机构再到专科诊所。关键的成长要素包括对阿片类药物副作用的认识提高、药物配方的进步以及医疗保健支出的增加。最新的机会在于个人化医疗方法，该方法侧重于针对患者的特定解决方案，并考虑影响便秘的遗传和生活方式因素。公司可以透过投资患者教育和开发全面的 OIC 管理计划来利用这些机会。然而，它面临着挑战​​，包括新药认证的严格监管要求、长期使用鸦片类药物带来的耻辱，以及准确诊断 OIC 和其他类型便秘的复杂性。创新研究领域包括开发非鸦片类药物疼痛管理解决方案，最大限度地减少或消除便秘风险，以及利用数位健康工具有效监测和管理症状。它还可以进行旨在阐明微生物组在 OIC 中的作用并发现新的治疗标靶的研究。儘管存在这些挑战，但随着人口老化和慢性疼痛盛行率的增加，OIC 治疗的全球市场预计将扩大。这一领域的从业者专注于开发以患者为中心的整体护理模式，以应对不断变化的监管标准，促进与医疗保健提供者的合作，并整合尖端的治疗方案，从而提高市场渗透率。

主要市场统计
基准年[2023] 6595万美元
预测年份 [2024] 7010 万美元
预测年份 [2030] 1.0378亿美元
复合年增长率（%） 6.69%

市场动态：揭示快速发展的阿片类药物引起的便秘市场的关键市场洞察

阿片类药物引起的便秘市场正因供需的动态交互作用而转变。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 便秘老年人口增多
    • 肾臟疾病盛行率增加
    • 扩大多种治疗方法的可用性
  • 市场限制因素
    • 核准流程严格，工作耗时
  • 市场机会
    • 扩大阿片类药物的使用
    • 零售药局的供应量增加
  • 市场挑战
    • 对阿片类药物耐受性和成瘾的担忧

波特的五力战略工具驾驭鸦片类药物引起的便秘市场

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解阿片类药物引起的便秘市场的外部影响

外部宏观环境因素在塑造阿片类药物引起的便秘市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解鸦片类药物引起的便秘市场的竞争格局

阿片类药物引起的便秘市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵供应商在鸦片类药物引起的便秘市场的绩效评估

FPNV 定位矩阵是评估鸦片类药物引起的便秘市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了阿片类药物引起的便秘市场的成功之路

对阿片类药物引起的便秘市场的策略分析对于旨在加强其在全球市场的影响力的公司至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 患有便秘併发症的老年人口不断增加
      • 肾臟疾病增加
      • 各种治疗方法的普及
    • 抑制因素
      • 核准流程严格、耗时
    • 机会
      • 阿片类药物的使用增加
      • 零售药局的供应量增加
    • 任务
      • 对阿片类药物耐受性和成瘾的担忧
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章活性成分阿片类药物引起的便秘市场

  • 膨胀性泻药、刺激性泻药
  • 多库酯钠
  • 软化剂/润滑剂 泻药
  • 鲁比前列酮
  • 溴化甲基纳曲酮
  • 纳洛昔康
  • 渗透性泻药
  • 琴酒/胃肠动力促进剂

第 7 章 按药物类别分類的鸦片类药物引起的便秘市场

  • 局部作用氯离子通道活化剂 (LAACCA)
  • 非选择性鸦片拮抗剂
  • 週边限制性μ阿片受体拮抗剂（PAMORA）
  • μ-阿片拮抗剂

第八章 依给药方式分類的鸦片类药物所引起的便秘市场

  • 口服
  • 胃肠外的

第九章阿片类药物引起的便秘市场：依通路

  • 药局
  • 医院药房
  • 独立药房

第10章美洲鸦片类药物引起的便秘市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太阿片类药物引起的便秘市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章 欧洲、中东和非洲阿片类药物引起的便秘市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • AstraZeneca PLC
  • Fresenius Kabi AG
  • GlaxoSmithKline PLC
  • Hikma Pharmaceuticals PLC
  • Ironwood Pharmaceuticals, Inc.
  • Lantheus
  • Mylan by Viatris Inc.
  • Pfizer, Inc.
  • RedHill Biopharma Inc.
  • Salix Pharmaceuticals by Bausch Health Companies Inc.
  • Shionogo & Co. Ltd.
  • SLA Pharma AG
  • Synergy Pharmaceuticals Inc.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-742BD5182A30

The Opioid Induced Constipation Market was valued at USD 65.95 million in 2023, expected to reach USD 70.10 million in 2024, and is projected to grow at a CAGR of 6.69%, to USD 103.78 million by 2030.

Opioid Induced Constipation (OIC) is a common side effect among patients using opioid analgesics for pain management, posing a significant area of interest for pharmaceutical companies and healthcare providers. The increasing prevalence of chronic pain and the subsequent rise in opioid consumption drive the necessity for effective OIC management solutions. Key applications include prescription medications, over-the-counter remedies, and non-pharmacological interventions aimed at alleviating constipation symptoms. The end-users span across hospitals, home care settings, and specialty clinics. Key growth influencers include the growing awareness surrounding opioid side effects, advancements in drug formulations, and increased healthcare spending. The latest opportunities lie in personalized medicine approaches, focusing on patient-specific solutions that consider genetic and lifestyle factors influencing constipation. Companies can capitalize on these opportunities by investing in patient education and developing comprehensive OIC management programs. However, market growth faces challenges such as stringent regulatory requirements for new drug approvals, the stigma associated with long-term opioid use, and the complexity of accurately diagnosing OIC versus other types of constipation. Innovation areas ripe for exploration include developing non-opioid pain management solutions that minimize or eliminate the risk of constipation, as well as leveraging digital health tools to monitor and manage symptoms effectively. Research can also be targeted towards understanding the microbiome's role in OIC, offering insights into novel therapeutic targets. Despite these challenges, the global market for OIC therapies is expected to grow as the aging population and incidence of chronic pain increase. Businesses within this niche can enhance market penetration by aligning with evolving regulatory standards, fostering collaborations with healthcare providers, and emphasizing the development of holistic and patient-centric care models that integrate cutting-edge treatment options.

KEY MARKET STATISTICS
Base Year [2023] USD 65.95 million
Estimated Year [2024] USD 70.10 million
Forecast Year [2030] USD 103.78 million
CAGR (%) 6.69%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Opioid Induced Constipation Market

The Opioid Induced Constipation Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising geriatric population with constipation complications
    • Growing prevalence of kidney disorders
    • Surging availability of diversified treatments
  • Market Restraints
    • Stringent approval process and time-consuming
  • Market Opportunities
    • Proliferating use of opioids
    • Rise in availability in retail pharmacies
  • Market Challenges
    • Concern regarding opioid tolerance and addiction

Porter's Five Forces: A Strategic Tool for Navigating the Opioid Induced Constipation Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Opioid Induced Constipation Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Opioid Induced Constipation Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Opioid Induced Constipation Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Opioid Induced Constipation Market

A detailed market share analysis in the Opioid Induced Constipation Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Opioid Induced Constipation Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Opioid Induced Constipation Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Opioid Induced Constipation Market

A strategic analysis of the Opioid Induced Constipation Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Opioid Induced Constipation Market, highlighting leading vendors and their innovative profiles. These include AstraZeneca PLC, Fresenius Kabi AG, GlaxoSmithKline PLC, Hikma Pharmaceuticals PLC, Ironwood Pharmaceuticals, Inc., Lantheus, Mylan by Viatris Inc., Pfizer, Inc., RedHill Biopharma Inc., Salix Pharmaceuticals by Bausch Health Companies Inc., Shionogo & Co. Ltd., SLA Pharma AG, Synergy Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Opioid Induced Constipation Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Active Ingredients, market is studied across Bulk Cathartics, Stimulant Cathartics, Docusate Sodium, Emollient/Lubricant Cathartics, Lubiprostone, Methylnaltrexone Bromide, Naloxegol, Osmotic laxatives, and Prostaglandins/Prokinetic Drugs.
  • Based on Drug Class, market is studied across Locally Acting Chloride Channel Activator (LACCA), Non-Selective Opioid Antagonist, Peripherally-Restricted μ-Opioid Receptor Antagonist (PAMORA), and μ-Opioid Antagonist.
  • Based on Mode of Administration, market is studied across Oral and Parenteral.
  • Based on Distribution Channel, market is studied across Drug Store, Hospital Pharmacies, and Independent Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising geriatric population with constipation complications
      • 5.1.1.2. Growing prevalence of kidney disorders
      • 5.1.1.3. Surging availability of diversified treatments
    • 5.1.2. Restraints
      • 5.1.2.1. Stringent approval process and time-consuming
    • 5.1.3. Opportunities
      • 5.1.3.1. Proliferating use of opioids
      • 5.1.3.2. Rise in availability in retail pharmacies
    • 5.1.4. Challenges
      • 5.1.4.1. Concern regarding opioid tolerance and addiction
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Opioid Induced Constipation Market, by Active Ingredients

  • 6.1. Introduction
  • 6.2. Bulk Cathartics, Stimulant Cathartics
  • 6.3. Docusate Sodium
  • 6.4. Emollient/Lubricant Cathartics
  • 6.5. Lubiprostone
  • 6.6. Methylnaltrexone Bromide
  • 6.7. Naloxegol
  • 6.8. Osmotic laxatives
  • 6.9. Prostaglandins/Prokinetic Drugs

7. Opioid Induced Constipation Market, by Drug Class

  • 7.1. Introduction
  • 7.2. Locally Acting Chloride Channel Activator (LACCA)
  • 7.3. Non-Selective Opioid Antagonist
  • 7.4. Peripherally-Restricted μ-Opioid Receptor Antagonist (PAMORA)
  • 7.5. μ-Opioid Antagonist

8. Opioid Induced Constipation Market, by Mode of Administration

  • 8.1. Introduction
  • 8.2. Oral
  • 8.3. Parenteral

9. Opioid Induced Constipation Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Drug Store
  • 9.3. Hospital Pharmacies
  • 9.4. Independent Pharmacies

10. Americas Opioid Induced Constipation Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Opioid Induced Constipation Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Opioid Induced Constipation Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AstraZeneca PLC
  • 2. Fresenius Kabi AG
  • 3. GlaxoSmithKline PLC
  • 4. Hikma Pharmaceuticals PLC
  • 5. Ironwood Pharmaceuticals, Inc.
  • 6. Lantheus
  • 7. Mylan by Viatris Inc.
  • 8. Pfizer, Inc.
  • 9. RedHill Biopharma Inc.
  • 10. Salix Pharmaceuticals by Bausch Health Companies Inc.
  • 11. Shionogo & Co. Ltd.
  • 12. SLA Pharma AG
  • 13. Synergy Pharmaceuticals Inc.
  • 14. Takeda Pharmaceutical Company Limited
  • 15. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. OPIOID INDUCED CONSTIPATION MARKET RESEARCH PROCESS
  • FIGURE 2. OPIOID INDUCED CONSTIPATION MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. OPIOID INDUCED CONSTIPATION MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. OPIOID INDUCED CONSTIPATION MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. OPIOID INDUCED CONSTIPATION MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. OPIOID INDUCED CONSTIPATION MARKET DYNAMICS
  • TABLE 7. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY BULK CATHARTICS, STIMULANT CATHARTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DOCUSATE SODIUM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY EMOLLIENT/LUBRICANT CATHARTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LUBIPROSTONE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY METHYLNALTREXONE BROMIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY NALOXEGOL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY OSMOTIC LAXATIVES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PROSTAGLANDINS/PROKINETIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LOCALLY ACTING CHLORIDE CHANNEL ACTIVATOR (LACCA), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY NON-SELECTIVE OPIOID ANTAGONIST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY-RESTRICTED M-OPIOID RECEPTOR ANTAGONIST (PAMORA), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY M-OPIOID ANTAGONIST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG STORE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
  • TABLE 60. AUSTRALIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 61. AUSTRALIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 62. AUSTRALIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 63. CHINA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
  • TABLE 64. CHINA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 65. CHINA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 66. CHINA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 67. INDIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
  • TABLE 68. INDIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 69. INDIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 70. INDIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 71. INDONESIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
  • TABLE 72. INDONESIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 73. INDONESIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 74. INDONESIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 75. JAPAN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
  • TABLE 76. JAPAN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 77. JAPAN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 78. JAPAN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 79. MALAYSIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
  • TABLE 80. MALAYSIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 81. MALAYSIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 82. MALAYSIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 83. PHILIPPINES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
  • TABLE 84. PHILIPPINES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 85. PHILIPPINES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 86. PHILIPPINES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 87. SINGAPORE OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
  • TABLE 88. SINGAPORE OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 89. SINGAPORE OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 90. SINGAPORE OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH KOREA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
  • TABLE 92. SOUTH KOREA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 93. SOUTH KOREA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 94. SOUTH KOREA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 95. TAIWAN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
  • TABLE 96. TAIWAN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 97. TAIWAN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 98. TAIWAN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 99. THAILAND OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
  • TABLE 100. THAILAND OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 101. THAILAND OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 102. THAILAND OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 103. VIETNAM OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
  • TABLE 104. VIETNAM OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 105. VIETNAM OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 106. VIETNAM OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 112. DENMARK OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
  • TABLE 113. DENMARK OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 114. DENMARK OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 115. DENMARK OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 116. EGYPT OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
  • TABLE 117. EGYPT OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 118. EGYPT OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 119. EGYPT OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 120. FINLAND OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
  • TABLE 121. FINLAND OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 122. FINLAND OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 123. FINLAND OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 124. FRANCE OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
  • TABLE 125. FRANCE OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 126. FRANCE OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 127. FRANCE OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 128. GERMANY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
  • TABLE 129. GERMANY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 130. GERMANY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 131. GERMANY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 132. ISRAEL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
  • TABLE 133. ISRAEL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 134. ISRAEL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 135. ISRAEL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 136. ITALY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
  • TABLE 137. ITALY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 138. ITALY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 139. ITALY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 140. NETHERLANDS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
  • TABLE 141. NETHERLANDS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 142. NETHERLANDS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 143. NETHERLANDS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 144. NIGERIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
  • TABLE 145. NIGERIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 146. NIGERIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 147. NIGERIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 148. NORWAY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
  • TABLE 149. NORWAY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 150. NORWAY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 151. NORWAY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 152. POLAND OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
  • TABLE 153. POLAND OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 154. POLAND OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 155. POLAND OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 156. QATAR OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
  • TABLE 157. QATAR OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 158. QATAR OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 159. QATAR OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 160. RUSSIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
  • TABLE 161. RUSSIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 162. RUSSIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 163. RUSSIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 164. SAUDI ARABIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
  • TABLE 165. SAUDI ARABIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 166. SAUDI ARABIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 167. SAUDI ARABIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
  • TABLE 169. SOUTH AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 170. SOUTH AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 171. SOUTH AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 172. SPAIN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
  • TABLE 173. SPAIN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 174. SPAIN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 175. SPAIN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 176. SWEDEN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
  • TABLE 177. SWEDEN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 178. SWEDEN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 179. SWEDEN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 180. SWITZERLAND OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
  • TABLE 181. SWITZERLAND OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 182. SWITZERLAND OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 183. SWITZERLAND OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 184. TURKEY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
  • TABLE 185. TURKEY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 186. TURKEY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 187. TURKEY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED ARAB EMIRATES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED ARAB EMIRATES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED ARAB EMIRATES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED KINGDOM OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
  • TABLE 193. UNITED KINGDOM OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 194. UNITED KINGDOM OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 195. UNITED KINGDOM OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 196. OPIOID INDUCED CONSTIPATION MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 197. OPIOID INDUCED CONSTIPATION MARKET, FPNV POSITIONING MATRIX, 2023